Therapeutic value of alpha-4 integrin blockade in inflammatory bowel disease: the role of natalizumab

被引：15

作者：

Ghosh, S ^{[1
]}

机构：

[1] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, London W12 0NN, England

来源：

EXPERT OPINION ON BIOLOGICAL THERAPY | 2003年 / 3卷 / 06期

关键词：

alpha(4) integrin; Crohn's disease; MADCAM-1; natalizumab;

D O I：

10.1517/eobt.3.6.995.21264

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 [微生物学]; 0836 [生物工程]; 090102 [作物遗传育种]; 100705 [微生物与生化药学];

摘要：

Lymphocyte infiltration into the intestinal tract in Crohn's disease is mediated by the interaction between a,, integrin, expressed on lymphocytes, and its ligand mucosal vascular addressin cell-adhesion molecule-1 (MADCAM-1), expressed on the endothelial cells of the microvasculature in inflamed intestinal tract. Natalizumab, a recombinant, humanised monoclonal antibody against alpha(4) integrin was effective in Crohn's disease in a Phase II, randomised, controlled trial. The highest response rate and remission rates were 71 and 44% at 6 weeks, respectively, after two infusions of 3 mg of natalizumab administered 4 weeks apart. Natalizumab was well-tolerated in this study. The Phase III trial results are awaited.

引用

收藏

页码：995 / 1000

页数：6

相关论文

共 9 条

[1]

Acquired increase in leucocyte binding by intestinal microvascular endothelium in inflammatory bowel disease [J].

Binion, DG ;

West, GA ;

Volk, EE ;

Drazba, JA ;

Ziats, NP ;

Petras, RE ;

Fiocchi, C .

LANCET, 1998, 352 (9142) :1742-1746

[2]

An ascending dose trial of a humanized A4B7 antibody in ulcerative colitis (UC). [J].

Feagan, BG ;

McDonald, J ;

Greenberg, G ;

Wild, G ;

Pare, P ;

Fedorak, RN ;

Landau, SB ;

Brettman, LR .

GASTROENTEROLOGY, 2000, 118 (04) :A874-A874

[3]

Natalizumab for active Crohn's disease. [J].

Ghosh, S ;

Goldin, E ;

Gordon, FH ;

Malchow, HA ;

Rask-Madsen, J ;

Rutgeerts, P ;

Vyhnalek, P ;

Zádorová, Z ;

Palmer, T ;

Donoghue, S .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (01) :24-32

[4]

A randomized placebo-controlled trial of a humanized monoclonal antibody to α4 integrin in active Crohn's disease [J].

Gordon, FH ;

Lai, CWY ;

Hamilton, MI ;

Allison, MC ;

Srivastava, ED ;

Fouweather, MG ;

Donoghue, S ;

Greenlees, C ;

Subhani, J ;

Amlot, PL ;

Pounder, RE .

GASTROENTEROLOGY, 2001, 121 (02) :268-274

[5]

A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to alpha-4 integrin [J].

Gordon, FH ;

Hamilton, MI ;

Donoghue, S ;

Greenlees, C ;

Palmer, T ;

Rowley-Jones, D ;

Dhillon, AP ;

Amlot, PL ;

Pounder, RE .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2002, 16 (04) :699-705

[6]

Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin alpha 4 beta 7 [J].

Hesterberg, PE ;

WinsorHines, D ;

Briskin, MJ ;

SolerFerran, D ;

Merrill, C ;

Mackay, CR ;

Newman, W ;

Ringler, DJ .

GASTROENTEROLOGY, 1996, 111 (05) :1373-1380

[7]

ATTENUATION OF COLITIS IN THE COTTON-TOP TAMARIN BY ANTI-ALPHA-4 INTEGRIN MONOCLONAL-ANTIBODY [J].

PODOLSKY, DK ;

LOBB, R ;

KING, N ;

BENJAMIN, CD ;

PEPINSKY, B ;

SEHGAL, P ;

DEBEAUMONT, M .

JOURNAL OF CLINICAL INVESTIGATION, 1993, 92 (01) :372-380

[8]

Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease [J].

Schreiber, S ;

Nikolaus, S ;

Malchow, H ;

Kruis, W ;

Lochs, H ;

Raedler, A ;

Hahn, EG ;

Krummenerl, T ;

Steinmann, G .

GASTROENTEROLOGY, 2001, 120 (06) :1339-1346

[9]

A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease [J].

Yacyshyn, BR ;

Bowen-Yacyshyn, MB ;

Jewell, L ;

Tami, JA ;

Bennett, CF ;

Kisner, DL ;

Shanahan, WR .

GASTROENTEROLOGY, 1998, 114 (06) :1133-1142